PremiumThe FlyBoundless Bio downgraded to Neutral from Buy at Guggenheim Boundless Bio Shifts Focus and Restructures Leadership Team Boundless Bio provides portfolio update PremiumThe FlyBoundless Bio announces departure of CFO Boundless Bio Adjusts Stock Options to Incentivize Key Staff Boundless Bio reports Q2 EPS (77c), consensus (80c) PremiumThe FlyBoundless Bio initiated with an Overweight at Piper Sandler Boundless Bio intiated with Not Rated at Goldman Sachs Opening Day: Ibotta soars in strong market debut